PAREA establishes new governance and leadership at founding General Assembly

Today marks an important milestone for PAREA as we elected our new Board of Directors and Office Bearers, and officially established the organisation as a legal non-profit entity, incorporated in Estonia! With three years of impactful work already behind us, this signifies a new step for PAREA, advancing our mission with renewed focus and autonomy.

 At today’s General Assembly, we elected our nine Board members, representing a wide range of expertise, including patient organisations, scientific and clinical societies, and psychedelic foundations. The Board also confirmed its leadership, electing Prof. David Nutt (Drug Science and Imperial College London) as PAREA Chair, Dr. Roxana Albu (Chief Scientific Officer, Association of European Cancer Leagues) as Vice-Chair, and Frédéric Destrebecq (Executive Director, European Brain Council) as Treasurer. We are excited to have an exceptional team on board, which will play a vital role in shaping PAREA’s vision and future endeavours. 

For more information, visit our Meet the Board page and stay tuned as we profile a different Board member each day on our social media channels.

The General Assembly also approved our founding articles of association and procedures, and adopted our Strategic and Work Plan for the upcoming years, laying a strong foundation for the work ahead.  

Transparency is a core value for us, and we are committed to openness and accountability. On our website, you can now find detailed information about our funding sources, including contributions received from industry, as well as a disclosure of conflicts of interest for each Board member. Additionally, we have introduced an Industry Partnership and Funding Framework to ensure our practices align with our mission and values.

Today marks the start of an exciting new chapter for PAREA, highlighting the growth of our organisation, the strength of our collaborations, and our shared dedication to advancing safe, effective, and accessible psychedelic therapies across Europe.